CRL Stock Analysis: Buy, Sell, or Hold?
CRL - Charles River Laboratories International, Inc.
$159.12
-3.73 (-2.29%)
▼
5d:
-12.42%
30d:
-11.87%
90d:
+0.24%
WAIT
LOW Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: May 07, 2026
0d
Get Alerted When CRL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: CRL is down 12.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: CRL is down 12.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$282.80
Based on 7.7% avg growth
INTRINSIC VALUE TODAY
$175.60
9.4% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 15.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CRL is currently trading at $159.12, which is considered oversold relative to its 30-day fair value range of $166.60 to $181.43. From a valuation perspective, the stock is trading at a discount (Forward PE: 13.2) compared to its historical average (15.8). Remarkably, the market is currently pricing in an annual earnings decline of 6.0% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, CRL is in a strong downtrend. The price is currently testing key support at $158.89. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $209.00 (+28.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CRL is in a strong downtrend. The price is currently testing key support at $158.89. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $209.00 (+28.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$166.60 -
$181.43
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 28.3% below Wall St target ($209.00)
- WARNING: Recommendation downgraded due to -12.4% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$166.60 -
$181.43
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$158.89
Resistance Level
$194.57
Current Trend
Strong Downtrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
13.16
Wall Street Target
$209.00
(+28.3%)
Revenue Growth (YoY)
1.2%
Earnings Growth (YoY)
-17.3%
Profit Margin
-4.6%
Valuation Discount vs History
-6.0% cheaper
PE vs Historical
13.2 vs 15.8
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-6.0%
(market-implied from PE analysis)
1-Year Target
$153.08
(-6%)
2-Year Target
$143.89
(-12%)
3-Year Target
$135.26
(-17%)
3-Yr Target (if PE normalizes)
(PE: 13→16)
$162.34
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.0, Growth: 11.4%)
$377.40
(+132%)
Base:
(SPY PE: 13.2, Growth: 11.4%)
$225.42
(+38%)
Bear:
(PE: 11.2, Growth: 11.4%)
$191.61
(+18%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 13.2 to 15.8
Stabilization Target:
$195.45
(+20.0%)
PE Expansion Potential:
+20.0%
Share & Embed Analysis
Last updated: May 14, 2026 4:44 PM ET
Data refreshes hourly during market hours. Next update: 5:44 PM
Data refreshes hourly during market hours. Next update: 5:44 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRL showing a specific setup today?
Insider Activity (6 Months)
1
Buys
1
Sells
0
Net
NEUTRAL
Recent Transactions
Ro Khanna
BUY
2026-03-30
Ro Khanna
SELL
2026-02-05
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
31 analysts |
$620 | 55 HOLD |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 65 BUY |
|
DHR
Danaher Corporation |
STRONG BUY
26 analysts |
$250 | 58 HOLD |
|
GH
Guardant Health Inc |
STRONG BUY
24 analysts |
$130 | 59 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$261 | 58 HOLD |
